These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

546 related items for PubMed ID: 16117983

  • 1. A retrospective analysis using Monte Carlo simulation to evaluate recommended ceftazidime dosing regimens in healthy volunteers, patients with cystic fibrosis, and patients in the intensive care unit.
    Mouton JW, Punt N, Vinks AA.
    Clin Ther; 2005 Jun; 27(6):762-72. PubMed ID: 16117983
    [Abstract] [Full Text] [Related]

  • 2. Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units.
    Roos JF, Bulitta J, Lipman J, Kirkpatrick CM.
    J Antimicrob Chemother; 2006 Nov; 58(5):987-93. PubMed ID: 16943209
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Population pharmacokinetic and pharmacodynamic modeling of high-dose intermittent ticarcillin-clavulanate administration in pediatric cystic fibrosis patients.
    Zobell JT, Stockmann C, Young DC, Cash J, McDowell BJ, Korgenski K, Sherwin CM, Spigarelli M, Chatfield BA, Ampofo K.
    Clin Ther; 2011 Nov; 33(11):1844-50. PubMed ID: 22018680
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Pharmacokinetic-pharmacodynamic target attainment analysis of doripenem in infected patients.
    Ikawa K, Morikawa N, Uehara S, Monden K, Yamada Y, Honda N, Kumon H.
    Int J Antimicrob Agents; 2009 Mar; 33(3):276-9. PubMed ID: 19095418
    [Abstract] [Full Text] [Related]

  • 8. Ceftazidime dosage recommendations in burn patients: from a population pharmacokinetic approach to clinical practice via Monte Carlo simulations.
    Conil JM, Georges B, Ravat F, Ruiz S, Seguin T, Metsu D, Fourcade O, Saivin S.
    Clin Ther; 2013 Oct; 35(10):1603-12. PubMed ID: 24094465
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The integrated use of pharmacokinetic and pharmacodynamic models for the definition of breakpoints.
    Stass H, Dalhoff A.
    Infection; 2005 Dec; 33 Suppl 2():29-35. PubMed ID: 16518709
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Determine Optimal Dosing of Ceftazidime-Avibactam for the Treatment of Acute Pulmonary Exacerbations in Patients with Cystic Fibrosis.
    Bensman TJ, Wang J, Jayne J, Fukushima L, Rao AP, D'Argenio DZ, Beringer PM.
    Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28784670
    [Abstract] [Full Text] [Related]

  • 14. [Pharmacodynamic interest of ceftazidime continuous infusion vs intermittent bolus administration in patients with severe nosocomial pneumonia].
    Cousson J, Floch T, Vernet-Garnier V, Appriou M, Petit JS, Jovenin N, Lamiable D, Hoizey G.
    Pathol Biol (Paris); 2005 Oct; 53(8-9):546-50. PubMed ID: 16023303
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.